perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.10.07.21264420;](https://doi.org/10.1101/2021.10.07.21264420) this version posted August 17, 2022. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

### **Abstract**

## **INTRODUCTION:**

Previous work showed the *in-vivo* presence of retinal amyloid in AD patients using

curcumin. We aimed to replicate these findings in an amyloid biomarker confirmed

cohort.

# **METHODS:**

Twenty-six AD patients (age 66 (+9), MMSE≥17) and 14 controls (age 71(+12)) used

one of three curcumin formulations: Longvida®, Theracurmin® and Novasol®.

Plasma levels were determined and pre- and post- curcumin retinal fluorescence

scans were visually assessed in all cases and quantitatively assessed in a subset.

# **RESULTS:**

Visual assessment showed no difference between AD patients and controls for pre-

and post-curcumin images. This was confirmed by quantitative analyses on a subset.

59 Mean conjugated plasma curcumin levels were 198.7 nM (Longvida<sup>®</sup>), 576.6 nM

60 (Theracurmin<sup>®</sup>) and 1605.8 nM (Novasol<sup>®</sup>).

# **DISCUSSION:**

We found no difference in retinal fluorescence betweenamyloid confirmed AD cases

- 64 and control participants, using Longvida<sup>®</sup> and two additional curcumin formulations.
- Additional replication studies in amyloid confirmed cohorts are needed to assess the

diagnostic value of retinal fluorescence as an AD biomarker.

#### **Background**

 Alzheimer's disease (AD) research over the last decades enabled clinicians to diagnose AD not only in the dementia end-stage but also in the prodromal and preclinical stages using biomarkers for amyloid, tau and neurodegeneration [1, 2]. AD pathology starts 15-20 years before symptom onset and is reflected by change of biomarkers in the preclinical stage [1]. This time-interval provides a window of opportunity for disease modifying drugs to potentially halt disease progression towards the end stage of AD: dementia [3]. As currently used biomarkers are time consuming, expensive and/or invasive, non-invasive easily accessible biomarkers are urgently needed to diagnose AD in the earliest stages, enabling timely selection of patients for trials and future medication. The retina is an extension of the central nervous system and might provide such a biomarker. As such the retina is increasingly studied for manifestations of AD as

 potential non-invasive AD biomarkers. For example, retinal thinning, changes in retinal vasculature and peripheral drusen have been described in AD patients [4-6]. More specifically related to AD pathology, three small studies reported visualization of retinal amyloid beta deposits *in-vivo* using curcumin, a polipotent polyphenol with fluorescent properties that binds to amyloid in post-mortem brain tissue [7-9]. The presence of retinal amyloid beta deposits is however not unequivocally proven, since we and other groups could not confirm amyloid beta deposits in post mortem retinal tissue [10-14]. Moreover, curcumin is known for its low bioavailability, and while several commercially available formulations enhancing curcumin plasma levels are 91 on the market, so far only one formulation (Longvida<sup>®</sup>) has been reported to visualize retinal amyloid[7].

 In the current study, we used three different curcumin formulations as labeling fluorophores in-vivo. Using a targeted fluorescence approach, we aimed to visualize retinal amyloid in a well-characterized and amyloid biomarker confirmed AD cohort. **Methods** *Participants* We enrolled 26 patients with AD (MMSE score ≥17) and 14 controls (MMSE ≥27) from two different cohorts – the Alzheimer Dementia Cohort (ADC) and the EMIF-AD PreclinAD study. All subjects underwent extensive screening according to a

standardized protocol described elsewhere [15, 16]. All patients fulfilled NIA-AA

criteria of AD with amyloid biomarker confirmation through either CSF amyloid beta1-

105  $_{42}$  (A $\beta_{42}$ ) analysis or amyloid-PET [1]. ADC controls had subjective cognitive decline,

defined as cognitive complaints without objective cognitive impairment on

neuropsychological exam, no signs of neurodegeneration on neuroimaging, and

absence of AD pathology based on CSF biomarkers and/or amyloid-PET. Exclusion

criteria for all participants were ophthalmological conditions interfering with retinal

scan quality, e.g. diabetic retinopathy, glaucoma or moderate/intermediate age

related macular degeneration.. In addition, we excluded subjects with ischemic stroke

and/or mild to severe white matter hyperintensities on MRI, operationalized as a

Fazekas score >2. We excluded two AD patients; one because of problems with eye

fixation due to visuoperceptive dysfunction and one because of participation in a drug

trial with disease modifying drugs. We excluded two controls; one due to problems

finishing the scan protocol because of dry eyes and one was found to have

glaucoma. Three AD patients were lost to follow up. This study was designed and

- conducted according to the Declaration of Helsinki and the study protocol was
- approved by the Ethical Committee of the VU University Medical Center. All patients
- gave their written informed consent in the presence of their caregiver.
- 
- *Amyloid biomarker assessment*
- Between 2016 and 2018, CSF concentrations of Aβ42, total tau, and tau
- phosphorylated at threonine 181 (pTau181) were measured using Innotest ELISAs
- (Fuijirebio, Ghent, Belgium). Between 2018 and 2020, these CSF biomarkers were
- 126 assessed using Elecsys Aβ<sub>1–42</sub> CSF, Elecsys total-tau CSF, and Elecsys pTau<sub>181</sub>
- CSF electrochemiluminescence immunoassays (Roche Diagnostics, Basel,
- Switzerland). For comparability Innotest CSF values were converted using previously
- 129 published conversion formulas [17]. A pTau/ Aβ42-ratio≥0.020 was considered an AD
- profile [18].
- 131 Amyloid-PET scanning was performed with either  $18F$ -Florbetaben (NeuraCeq),  $18F$ -
- Florbetapir (Amyvid) or 18F-Flutemetamol (Vizamyl) tracers [19-21]. An experienced
- nuclear physician (BvB) who completed training for all radiotracers visually assessed

images of amyloid-PET scans as positive or negative.

- 
- *Ophthalmological assessment*

 Subjects underwent the following general eye examination: best corrected visual acuity (VA), intraocular pressure (IOP) using non-contact tonometry, and slit-lamp examination of the anterior and posterior segment, followed by administration of tropicamide 0.5% to dilate the pupil for optimal retinal imaging. An experienced ophthalmologist (FDV) interpreted all examinations.

# *Heidelberg HRA SLO imaging*



25]. With Novasol we acquired images using a 55° lens in six ROI's (central macula,

 superior, temporal, inferior, superior-temporal and inferior-temporal) at baseline and 2 hours after the fifth dose (Figure 1A-B).

*Retinal fluorescence image analysis*

 Baseline and post-curcumin-administration images were assessed both visually and quantitatively. Visual assessment was performed by an experienced ophthalmologist, masked for diagnosis and curcumin treatment (FDV). Baseline and post-curcumin- administration images of AD patients were compared for the Novasol cohort and also between AD and control subjects for the Theracurmin and Longvida cohort. To 177 support the visual assessment, we used the Longvida<sup>®</sup> cohort for quantitative 178 analysis, allowing comparison to previous publications using Longvida<sup>®</sup> as curcumin derivative. Images of the right eye with sufficient image quality (scans that were out of focus, had extensive shading or extreme low/high contrast hampering co- registration were excluded) were assessed for quantitative analysis (Figure 1C). Retinal fluorescence imaging yielded 8-bit grayscale images sized 1536 x 1566 or 768 x 798 pixels with a resolution of 6 or 12 µm respectively per pixel. The non- normalized, uncompressed images were compared between time points using MATLAB 2020b (MathWorks). An image pair of two time points of similar ROI's were cropped to a size of 1430 x 1430 or 715 x 715 pixels to remove the manufacturer logo and blurry edges. In the case any image pair contained high resolution images (1430 x 1430) the images were down-sampled to match the size of 715 x 715 pixels. Afterwards, both images were flat-field corrected to compensate for any illumination and shading effect. A registration algorithm (feature-based registration (SURF: Speeded-Up Robust Features) with affine transformation, allowing for rotation) was used to register matched images [26]. If an automatic match was not obtained, the

 software interrupted and allowed for manual picking of identical points of interest in both images and creating a registration match based on the user's input (using the same registration algorithm). Registered images were cropped to a size of 512 x 512 pixels, ensuring that both images overlapped within the imaged field of view. Brightness histograms of both images were obtained and matched (using a cubic polynomial) to the histogram of the baseline image, resulting in images with similar contrast and overall brightness. We defined focal retinal hyperfluorescence, by selecting areas of ≥4 adjacent pixels that represented the 10% highest pixel value in 201 the post-curcumin image. These hyperfluorescence spots were labeled, and their area and brightness measured. The same properties were measured in the baseline image, using the exact same spots (as identified in the post-curcumin image). Afterwards, the brightness difference between each hyperfluorescence spot was calculated.

#### *Curcuminoids plasma level analysis*

 Blood was drawn in heparinized tubes that were directly kept in aluminum foil on ice, to avoid degradation by light and temperature. Within 30 minutes, plasma and serum were separated and plasma was stored at minus 80°C in the Amsterdam UMC Biobank. High Performance Liquid Chromatography-Tandem Mass Spectroscopy (HPLC-MS-MS) analysis was performed to measure different curcuminoids: curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin. Each sample was treated, in duplicates, with and without β-glucuronidase after which unconjugated and conjugated curcuminoids were quantified. Treatment with β- glucuronidase hydrolyzes the conjugated curcuminoids leading to an increase in unconjugated curcuminoids, whereas untreated samples were quantified on

 unconjugated curcumin at that point of time. Our validated method of analysis can be described, in short, as follows: Liquid-liquid extraction with Tert Butyl Methyl Ether (TBME) was used to extract the compounds from the plasma [27]. The HPLC-MS/MS system consisted of an Ultimate 3000 autosampler and pump, both of Dionex, connected to a degasser from LC Packings. The autosampler, with a 100 µL sample loop, was coupled to an Sciex API4000 mass spectrometer. A total of 50 µL sample was injected after which separation of the analytes was performed with an Agilent column 2.1x100mm packed with material of Zorbax Extend 3.5 µm C-18. The flowrate was 0.200µL/min and the dual gradient mobile phase consisted of A: ultra- purified H2O with 0.1% formic acid and B: MeOH 100%. The applied gradient profile started at 50:50 A:B and increased linear to 95% B in 3.0 minutes. During 6 minutes a 5:95 A:B level is continued, after which it returned in 0.2 minutes to 50:50. Afterwards the system was equilibrated during 6 minutes at the starting level. Throughout the liquid-liquid extraction and HPLC-MS/MS the potential influence of light brought back to a minimum by working in a dark environment. Each analytical run included a set of freshly prepared calibration samples containing all compounds in the validated range of 2 nM to 400 nM. Each compound was validated with its own deuterated internal standard.

*Statistical analysis*

 SPSS version 26.0 (IBM, Armonk, NY, USA) was used to assess group differences in demographics, curcumin data and quantitative retinal fluorescence. Chi squared test was used for dichotomous variables, independent sample T-test was used for continuous variables that were normally distributed and Mann Whitney U Test was used for non-normal distributed variables. Quantitative comparison of focal retinal

hyperfluorescence between AD patients and controls was assessed by calculating

the number of focal retinal hyperfluorescent pixels defined as a value in the top 10%

value range at baseline and after curcumin, for all retinal regions of the right eye.

Between group differences were assessed using a Mann Whitney U test.

Significance level for all tests was set at 0.05.

### **Results**

Group demographics of AD and control cases are shown in table 1, and

supplemental table 1 shows data for each individual participant. The control group

comprised more female participants. No differences were found for age between AD

and control group. As expected, and by design, we found significant group

differences for MMSE as well as CSF and amyloid-PET biomarkers. Table 2A shows

the demographics of the sub group used for the quantitative analysis. No statistical

256 group differences in age and sex were found.

*Qualitative and quantitative retinal fluorescence analysis*

 No scans were excluded for the qualitative analysis. The qualitative assessment of images pre- and post-curcumin intake by an experienced ophthalmologist (FDV) masked for the clinical diagnosis did not show differences in focal hyperfluorescence 262 in the ROI's, for either AD patients (Longvida<sup>®</sup>, Theracurmin<sup>®</sup> and Novasol<sup>®</sup>) or 263 controls (Longvida<sup>®</sup> and Theracurmin<sup>®</sup>)(Figure 2 and supplemental Figures 1 and 2). 264 The Longvida<sup>®</sup> cohort was used for quantitative analysis. For the quantitative analysis one out of 12 control cases (case #10, see Supplemental Table 1) was excluded, as our algorithms were unable to find a good registration between time points. This applied to a total of 24 regions of a total of 10 patients, while the other



## **Discussion**

 In this study we aimed to discriminate AD patients from controls with a targeted fluorescence approach of the retina using curcumin as fluorophore in a well- characterized AD biomarker confirmed cohort. Using three different curcumin formulations, we did not find differences in focal retinal hyperfluorescence before or after curcumin intake between diagnostic groups, despite an observed overall increase in retinal fluorescence after curcumin intake.

 Our negative findings may be explained by a low intensity of the fluorescent signal resulting from (amyloid-bound) curcumin, insufficient binding of unconjugated curcumin to retinal amyloid, absence of retinal amyloid (in this subset of patients) or methodological limitations of our scanning and analysis methods.

 Fluorescence of curcumin largely overlaps with autofluorescence of the retina. This might therefore mask subtle signals of curcumin fluorescence hypothesized to be the result of retinal amyloid (plaque) pathology, reported to be approximately 5-20µm in size [7]. At present no data is available describing the magnitude of fluorescent signal that can be expected from retinal amyloid relative to retinal autofluorescence. On visual inspection we could identify a certain number of hyperfluorescent spots (Figure 3, zoom-ins), however there was no difference between AD patients and controls in these spots, either in size or intensity, neither at baseline, nor after curcumin intake. To increase sensitivity for weak retinal fluorescent signal possibly overlooked by visual inspection, we performed a quantitative analysis on a subset of participants (14 AD, 11 controls) who received Longvida confirming findings of the visual inspection.

 The absence of a fluorescent signal after curcumin intake could also be explained by insufficient curcuminbinding to retinal amyloid due to low plasma levels of unconjugated curcumin. After deconjugation using β-glucuronidase we observed high blood levels of total curcumin, in line with previous studies [22, 24]. In contrast, Koronyo *et al.* found high levels of unconjugated curcumin (400nM) without using β- glucuronidase [7]. This could be attributed to their different analysis methods: 1. wider/broader calibration settings. 2. internal standards without deuterated forms and validated in mouse. 3. acidification instead of freezing to stabilize samples .

 Nevertheless, conjugated forms of curcumin are known to bind to amyloid as well following ex-vivo application to post-mortem brain sections [28]. And penetration of curcumin in the retina is suggested by our quantitative analysis where a general increase in fluorescence was observed after curcumin intake (data not shown), implying that curcumin with the capacity to bind fibrillar amyloid reached the retina. 322 Despite 3-4 times higher plasma levels of curcumin conjugates using Theracurmin<sup>®</sup> 323 and Novasol<sup>®</sup> compared to Longvida<sup>®</sup> in this study, we found no difference in focal retinal hyperfluorescence between AD patients and controls.

 The lack of between-group differences in our study could also be explained by absence of amyloid in the retina. The presence of (fibrillar) amyloid in the human retina is not unequivocally proven, as three labs showed positive staining with 6E10 and 12F4 antibodies interpreted as presence of retinal amyloid plaques in post- mortem retinas, while others were unable to replicate these findings [7, 10, 12, 13, 29, 30]. Methodological heterogeneity in post-mortem study methods might account for these discrepancies. Replication studies and harmonization of study methods are needed to overcome these discrepancies before the presence of retinal amyloid in AD can undoubtedly be confirmed. This is one of the key goals of 'The Eye as a Biomarker for AD' Personal Interest Area of the Alzheimer's Association.

 Three previous studies showed hyperfluorescence in AD cases after curcumin intake [7-9]. While these studies were of similar small sample size, AD biomarker confirmation was lacking, which is essential when relating retinal changes to AD, since other structures may cause changes in fluorescence as well. For example, retinal drusen, associated with macular degeneration, contain amyloid and other age-

 related deposits [31, 32]. This may account for the positive findings in Koronyo's study where AD patients had a mean age of 76 years compared to 53 years in controls [7]. More work is needed to discriminate normal aging from pathological neurodegenerative changes in the retina underlying the observed changes in retinal fluorescence.

 There are some limitations of this study, potentially explaining the negative findings. First, our scan timing might have been suboptimal for measuring curcumin bound to retinal amyloid resulting in impaired sensitivity. The optimal time point to measure retinal fluorescence is still to be determined. We based our scan timing on previously published pharmacokinetic curves of systemically available curcumin representing assumed peak levels of systemic curcumin, as has been shown to yield signal before [7, 22-25]. Second, the quantitative analysis could not be applied on the full cohort because of variation in imaging protocols. Also the fluorescent signal itself, is directly affected by illumination differences within images and between time points. These small alterations in scan quality may affect the co-registration of baseline and follow up scans and the signal itself. We applied several algorithms correcting for differences in illumination and scan quality. We are open to sharing our raw data, enabling application of other algorithms.

 In conclusion, we found no differences in focal retinal hyperfluorescence between AD 363 patients and controls pre- and post-curcumin, using Longvida<sup>®</sup>, a curcumin formulation previously used for this purpose. As we could not replicate previous findings with similar methods in our amyloid biomarker-confirmed cohort, we question whether focal retinal hyperfluorescence represents retinal amyloid, or rather age-

- 367 related changes. Based on our analysis, retinal hyperfluorescence imaging using
- 368 oral curcumin as labeling fluorophore is currently not ready for use as AD biomarker.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2021.10.07.21264420;](https://doi.org/10.1101/2021.10.07.21264420) this version posted August 17, 2022. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### **References**

- 1. Jack, C.R., Jr., et al., *NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.* Alzheimers Dement, 2018. **14**(4): p. 535- 562.
- 2. Sperling, R.A., et al., *Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.* Alzheimers Dement, 2011. **7**(3): p. 280-92.
- 3. Scheltens, P., et al., *Alzheimer's disease.* Lancet, 2021. **397**(10284): p. 1577- 1590.
- 4. Alber, J., et al., *Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward.* Alzheimers Dement, 2020. **16**(1): p. 229-243.
- 5. Gupta, V.B., et al., *Retinal changes in Alzheimer's disease- integrated prospects of imaging, functional and molecular advances.* Prog Retin Eye Res, 2021. **82**: p. 100899.
- 6. Snyder, P.J., et al., *Retinal imaging in Alzheimer's and neurodegenerative diseases.* Alzheimers Dement, 2021. **17**(1): p. 103-111.
- 7. Koronyo, Y., et al., *Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.* JCI Insight, 2017. **2**(16).
- 8. Tadokoro, K., et al., *Retinal Amyloid Imaging for Screening Alzheimer's Disease.* J Alzheimers Dis, 2021.
- 9. Ngolab, J., et al., *Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial.* Alzheimers Dement (Amst), 2021. **13**(1): p. e12199.
- 10. den Haan, J., et al., *Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas.* Acta Neuropathol Commun, 2018. **6**(1): p. 147.
- 11. Jiang, J., et al., *Amyloid Plaques in Retina for Diagnosis in Alzheimer's Patients: a Meta-Analysis.* Front Aging Neurosci, 2016. **8**: p. 267.
- 12. Williams, E.A., et al., *Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease.* J Neuropathol Exp Neurol, 2017. **76**(5): p. 376-383.
- 13. Ho, C.Y., et al., *Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.* Brain Pathol, 2014. **24**(1): p. 25-32.
- 14. Schon, C., et al., *Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice.* PLoS One, 2012. **7**(12): p. e53547.
- 15. Konijnenberg, E., et al., *The EMIF-AD PreclinAD study: study design and baseline cohort overview.* Alzheimers Res Ther, 2018. **10**(1): p. 75.
- 16. van der Flier, W.M. and P. Scheltens, *Amsterdam Dementia Cohort: Performing Research to Optimize Care.* J Alzheimers Dis, 2018. **62**(3): p. 1091-1111.
- 17. Willemse, E.A.J., et al., *Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.* Alzheimers Dement (Amst), 2018. **10**: p. 563-572.
- 18. Willemse, E.A.J., et al., *Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.* Alzheimers Dement (Amst), 2021. **13**(1): p. e12182.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.10.07.21264420;](https://doi.org/10.1101/2021.10.07.21264420) this version posted August 17, 2022. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted





## 462 **Authors' contributions**



463

#### **Conflicts of interest**

 Research of CT is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. CT is recipients of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than [30 partners](https://www.alzheimer-nederland.nl/onderzoek/projecten/aboard/partners) participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. CT has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC- Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon. FB has a collaboration contract with Biogen, Optina Dx and Roche. Payments are made to the institution of VUMC. FB is committee member of EAN and chairs the atypical AD PIA and the Eye as biomarker for AD PIA of ISTAART. PS is chair steering committee in NOVARTIS, member DSMB GENENTECH, global PI phase s! study AC IMMUNE, member advisory board AXON NEUROSCIENCE, global PI phase 2B study EIP PHARMA, PI phase 2B study COGRX, member advisory board GEMVAX, COGNOPTIX and CORTEXZYME, member strategic innovation committee GREEN VALLEY, PI global phase 2B study Vivoryon, PI global phase 2A study TOYAMA / FUJI FILM, PI global phase 1A study IONIS, personal fees from Life Science Partners Amsterdam, outside the submitted work. JB is supported for the current study by NWO (Foundation for scientific research in the Netherlands, similar to NIH and NSF) and Co-financing by Heidelberg engineering as part of the competitive research proposal,



perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.10.07.21264420;](https://doi.org/10.1101/2021.10.07.21264420) this version posted August 17, 2022. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

### 511 **Tables**

# 512 **Table 1. Demographics**



513

514 CSF data (presented as pg/ml) was available in 20 AD cases and 5 controls.

515 Amyloid-PET data (visual read) was available in 17 AD cases and 13 controls. <sup>a</sup>Chi

516 squared test, <sup>b</sup>independent sample T-test, <sup>c</sup>Mann Whitney-U test. \*3 controls had a

517 borderline positive biomarker profile, with a negative amyloid-PET. Abbreviations: SD

 $518$  = standard deviation; MMSE = mini mental state exam; IQR = interquartile range;

519 pTau = phosphorylated tau; CSF = cerebral spinal fluid.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.10.07.21264420;](https://doi.org/10.1101/2021.10.07.21264420) this version posted August 17, 2022. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

## 521 **Table 2** 522 **A) Demographics Longvida® Subgroup Quantitative analysis**



523

# 524 **B) Quantitative analysis**

<sup>525</sup>

<b>Number of increased spots</b>	AD		<b>CN</b>		
	Mean	<b>SD</b>	Mean	<b>SD</b>	p-value
Macula	29.5	23.4	46.5	51.7	0.748
Temporal	40.5	28.2	47.8	45.3	0.809
Inferior	52.6	62.0	37.9	46.1	0.705
Inferior-Temporal	33.3	22.0	28.0	28.9	0.403
Superior	39.1	47.4	29.2	25.2	0.905
Superior-Temporal	44.4	35.6	44.6	36.7	1.000

<sup>526</sup> 527



 A) CSF data (presented as pg/ml) was available in 8 AD cases and 4 controls. Amyloid-PET data (visual read) was available in 7 AD cases and 12 controls. aChi squared test, bIndependent sample T-test, cMann Whitney-U test. \*3 controls had a borderline positive biomarker profile, with a negative amyloid-PET. Abbreviations: AD = Alzheimer's disease, CN =Controls, SD = standard deviation; MMSE = mini mental 534 state exam;  $IQR =$  interquartile range;  $pTau =$  phosphorylated tau;  $CSF =$  cerebral spinal fluid. B) Results of quantitative analyses of images obtained with 30-degree lens showing 537 the number of spots with and increased or decreased pixel value after Longvida®

curcumin intake compared to baseline in all retinal regions for 14 AD and 12 control

participants. Data is presented as mean and standard deviations. Group comparisons

were made using a Mann Whitney U Test.

# 543 **Table 3. Curcuminoids plasma levels**



544

545 Plasma levels (mean ±SD) of different curcuminoids (curcumin, demethoxycurcumin,

546 bisdemethoxycurcumin and tetrahydrocurcumin) and total curcuminoids after β-

547 glucuronidase treatment in nanomolar (nM). Time points for serum level

548 measurement after the start of curcumin intake were 10 days for Longvida<sup>®</sup> and 5

549 days for Theracurmin<sup>®</sup> and Novasol<sup>®</sup>.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2021.10.07.21264420;](https://doi.org/10.1101/2021.10.07.21264420) this version posted August 17, 2022. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

### 551 **Figures**





## 555 **Figure 1. Visual representation of study protocol**

556 A. Timing of imaging, blood draw and curcumin intake of cohort 1 (Longvida<sup>®</sup>, 4000 557 mg for 10 days), cohort 2 (Theracurmin<sup>®</sup>, 180 mg for 5 days) and cohort 3 (Novasol<sup>®</sup>, 558 300 mg for 4 days, 500 mg for 1 day). B. Imaging protocol of cohort 1, 2 and 3. C.

559 Quantitative analysis.



## **Figure 2. Pre- and post-curcumin retinal fluorescence images for AD and control participants using Longvida**®

- Pre-and post-curcumin retinal fluorescence images using blue auto fluorescence (λ=486nm) in 6 retinal regions in a representative AD patient and control. Magnifications show incidental focal hyperfluorescence, both on baseline and after curcumin in AD and control participants. Abbreviations: TS= temporal-superior, S= superior, T= temporal, M= macula, TI= temporal-inferior, I= inferior.
	-





# **Figure 3. Plasma levels of total curcuminoids after Longvida**®**, Theracurmin**® 567

# **and Novasol**® 568 **intake measured with HPLC-MS/MS**

569 Overview of plasma levels of total curcuminoids after Longvida®, Theracurmin® and

570 Novasol<sup>®</sup> intake. Curcumin, demethoxycurcumin, bisdemethoxycurcumin and

571 tetrahydrocurcumin as measured with HPLC-MS/MS after β-glucuronidase treatment,

572 summed as total curcuminoids in nanomolar (nM).

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.10.07.21264420;](https://doi.org/10.1101/2021.10.07.21264420) this version posted August 17, 2022. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

### 574 **Supplemental material**

### 575 **Supplemental table 1. Demographics for each individual participant**



576

577 Cohort characteristics of participants enrolled in cohort 1 (Longvida<sup>®</sup>), cohort 2

578 (Theracurmin<sup>®</sup>) and cohort 3 (Novasol<sup>®</sup>). CSF data is presented as pg/ml. pTau/Aβ

579 ratio ≥ 0.020 was considered as AD profile.<sup>17</sup> Abbreviations: # = Participant Number,

580 Dx =Diagnosis, MMSE = Mini-Mental State Examination, CSF = Cerebrospinal Fluid,

581 Aβ = Amyloid-beta, pTau = Phosphorylated Tau, + = positive, - = negative, n.a. = not

582 available.





# 585 **Supplemental Figure 1. Pre- and post-curcumin retinal fluorescence images for**

## **AD patients and controls using Novasol**® 586

- 587 Pre-and post-curcumin retinal fluorescence images with a 55-degree lens using blue
- 588 auto fluorescence (λ=486nm) in 6 retinal regions in a representative Alzheimer's
- 589 disease (AD) patient. Abbreviations: TS= temporal-superior, S= superior, T=
- 590 temporal, M= macula, TI= temporal-inferior, I= inferior.



## **Alzheimer's Disease**

592

### 593 **Supplemental Figure 2. Pre- and post-curcumin retinal fluorescence images for AD**

### 594 **patients and controls using Theracurmin**®

- 595 Pre-and post-curcumin retinal fluorescence images with a 30-degree lens using blue auto
- 596 fluorescence (λ=486nm) in 2 retinal regions in a representative Alzheimer's disease (AD)
- 597 patient and control. Abbreviations: M= macula, T= temporal.
- 598